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Magnetic resonance imaging 
a b s t r a c t 
We report the case of a young adult which survived to anaphylactic shock caused by 
gadolinium-based contrast agent (GBCA) contrast agent infusion. The patient had no comor- 
bidities and previous history of allergic reactions to contrast agents and underwent elective 
magnetic resonance imaging (MRI) for parotid swelling. Seven years before he received intra- 
venous GBCA administration during an MRI, which exact chemical composition is unknown, 
without any allergic reaction. After intravenous injection of GBCA for MRI the patient devel- 
oped anaphylactic shock, causing respiratory failure, cardiac arrest, and cardiogenic shock 
after return of spontaneous circulation. Because of the rarity of the described event, this 
report has the aim to raise awareness in the healthcare personnel of the possibility of these 
life-threatening adverse reactions from GBCAs also in a patient without history of allergy to 
contrast agents and suggest a possible clinical management of these patients. 
© 2020 Published by Elsevier Inc. on behalf of University of Washington. 
This is an open access article under the CC BY-NC-ND license. 











Gadolinium-based contrast agents (GBCAs) have been ap-
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of a delay both in the diagnosis and in the first-line treatment
provided. 
Case report 
A 45-year-old Caucasian man without comorbidities and
previous history of allergic reactions to medications or con-
trast agents, underwent MRI for parotid swelling. Seven years
before, the patient underwent MRI including GBCA adminis-
tration for suspected parotid neoplasia without any allergic
reaction. Two minutes after the end of the intravenous admin-
istration of 0.2 mL/kg of Dotarem (active substance: gadoteric
acid) with an infusion rate of 1.5 mL/sec, followed by 20 mL
of cristalloids, the patient showed stinging cough, dyspnea,
unleashed nausea, and desaturation. The MRI scanner was
located within the hospital, so the hospital outreach team
for emergencies was promptly alerted and arrived in the MRI
rooms after 2 minutes: the patient was unconscious, apneic,
in cardiac arrest with asystole. Advanced life support was
immediately provided including intravenous administration
of adrenaline (1 mg repeated every second loop during cardio-
pulmonary resuscitation (CPR), then 0.1 μg/kg/min in con-
tinuous infusion), massive fluid infusion (around 1.5 L in 10
minutes), glucocorticoids at high dosage (1 g of hydrocortisone
during the arrest, followed by 60 mg every 6 hours in the next
24 hours), and endotracheal intubation despite severe glottic
edema. A defibrillation rhythm was obtained after 8 minutes
and a stable pulse after 18 minutes with multiple DC shocks
and epinephrine continuous infusion. After intensive care
unit admission, we started immediately with the brain protec-
tion protocol including deep sedation, maintaining of mean
arterial pressure > 80 mm Hg by epinephrine and scrupulous
normothermia by external cooling. In the initial hours, pa-
tient developed tight bronchospasm and progressive diffuse
urticaria that were managed with inhaled salbutamol, gluco-
corticoids, and H1 antihistamines. Four hours after admission,
the persistence of low cardiac output (1.4 L/min/m 2 , obtained
with transpulmonary thermodilution method), global akine-
sia, and ventricular left apoplexy by echocardiography, low
progression of R wave from V1 to V3 and the elevated troponin
I values, led us to perform coronary angiography for excluding
a coexisting coronary disease. The angiography did not show
any defect in coronary perfusion and, in the following hours,
cardiac and respiratory failure progressively improved with
rapid weaning of epinephrine. At 24 hours, the neurologic
examination during the interruption of sedation showed no
deficits with Glasgow Coma Scale 11/15 (intubated) and, thus,
the patient was rapidly extubated. He was discharged 24
hours later from ICU and, finally, at home without any cardiac
and neurological dysfunction 4 days after the event. 
Discussion 
In the last decades, magnetic resonance contrast media
have been recognized to have an excellent safety profile
[1 ,2] . In fact, the rate of adverse reactions after injectionof MRI contrast media is low, ranging between 0.07% and
0.8%, with an incidence of severe anaphylactoid reactions of
around 1 out of 10,000 patients [1–9] . Although cases of severe
immediate hypersensitivity reactions with cardiovascular
and respiratory impairment have been reported [10 ,11] , the
most common immediate hypersensitivity symptoms are
mild pruritus and urticaria [5 ,9] . An article published in 2017
reported the case of a young healthy adult man dying after
a severe immediate anaphylactic reaction to gadobutrol, a
GBCA agent administered for elective MRI [12] . Reasons of
death were brain swelling and hypoxia due to a prolonged
state of cardiac arrest. In this case is interesting that the
patient had undergone also contrast-enhanced CT previously
without the occurrence of any adverse effects. 
The role of immunoglobulin E–mediated reaction has been
advocated in hypersensitivity reactions, with a risk increased
up to 8 times and more severe responses at the second GBCAs
use in patients with history of hypersensitivity [11 ,13] . Skin
testing with different GBCAs after hypersensitivity reactions
are suggested for identifying the best tolerated agent, but the
true meaning of positive and negative results of the tests are
still unclear [11] . Our patient received GBCA 7 year before, but
he referred no specific reactions at that time. 
Stress-related cardiomyopathy seems to play a pivotal
role in severe myocardial dysfunction occurring during ana-
phylactic shock. Unfortunately, resuscitation maneuvers may
further potentiate cardiac dysfunction because of sympa-
thetic nervous system upregulation and increase of serum
catecholamine concentrations. In fact, several studies suggest
that an excessive β1-adrenergic stimulation by epinephrine
may induce left ventricular dysfunction. This may explain the
profound and persistent myocardial dysfunction observed
in our patient. Nevertheless, eco and electrocardiography
findings combined to troponin values did not allow us to
definitively rule out a coronary heart disease and, thus, we
decided for angiography. In anaphylaxis, systemic vasodilata-
tion, reduced venous return, and volume loss by increased
vascular permeability may lead to low cardiac output and
hypotension, which can induce coronary hypo-perfusion and
myocardial damage, particularly in patients with preexisting
coronary disease [14 ,15] . 
We believe that is important to report this severe anaphy-
lactic reaction by GBCA because of the rarity of the described
events [16] . Despite occasional, healthcare personnel and pa-
tients should be aware of the possibility of life-threatening or
fatal anaphylaxis from GBCAs also in a patient without history
of allergy to contrast agents. In fact, in a recently published ar-
ticle, was suggested to maintain the intravenous catheter as
long as needed to be sure the patient is not having any seri-
ous adverse reactions [17] . The report provides also useful in-
formation for the management of patients with persisting car-
diogenic shock after anaphylaxis, particularly for the interpre-
tation of echocardiography and electrocardiography signs and
for the role and timing of coronary angiography in this setting.
Supplementary materials 
Supplementary material associated with this article can be
found, in the online version, at doi: 10.1016/j.radcr.2019.12.006 .
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